The countdown to ESC Congress 2019 is nearing its end. The world's premier Cardiovascular congress is now less than four weeks away with the programme spanning from Saturday August 31 to Wednesday September 4.
Among the late-breaking science sessions, Proessor. Müller will present the data of the GALACTIC trial (“Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomised controlled trial”) at 11:36 on Monday in the main auditorium. Also, the main results of THEMIS (“Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study”) and ISAR-REACT 5 (“Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome”) will be presented and discussed on Sunday at 14:30 and 17:16, respectively.
ESC TV will be broadcasting throughout the congress. Indeed, the PARAGON-HF (“Angiotensin Receptor Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction”) trial will be discussed by Scott Solomon on Sunday at 16:25. Stay tuned to the right channel!
Make sure that you also look out for the AFIRE (“Rivaroxaban monotherapy versus combination therapy in patients with atrial fibrillation and stable coronary artery disease”) data which will be disclosed on Monday at 11:18.
Regarding the LEODOR study (“repetitive use of levosimendan in advanced heart failure patients”), an investigator meeting will be held to discuss initiation and enrollment of the patients at the centers. The study protocol will be discussed in a satellite symposium in “The HUB Duras” on Monday from 13:00 to 13:45.
The chairpersons of the symposium will be John T PARISSIS (Athens, Greece) and Francesco FEDELE (Roma, Italy), while the lectures and discussions will be held by Finn GUSTAFSSON (Copenhagen, Denmark), Veli-Pekka HARJOLA (Helsinki, Finland), yours truly Gerhard POLZL (Innsbruck, Austria), Josep COMIN-COLET (Hospitalet De Llobregat, Spain), Piergiuseppe AGOSTONI (Milan, Italy), and Carsten TSCHOEPE (Berlin, Germany).
The use of inotropes for correcting haemodynamic dysfunction and relieving symptoms in patients with congestive heart failure will be debated. Unfortunately, negative or insufficient data has been collected on the effects of cardiac glycosides, catecholamines and phosphodiesterase inhibitors on quality of life and survival. However, drugs which are both calcium sensitisers and potassium channel openers – such as levosimendan - have been proposed as safer inodilators in acute and advanced heart failure. Come and join the debate…